Dr. Jackman on Benefits of Liquid Biopsies in Lung Cancer

David M. Jackman
Published: Friday, Feb 03, 2017



David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.

One of the things that makes liquid biopsies exciting is the ability to test patients whose tumor tissue was inadequate for other testing, Jackman explains. Patients who either had insufficient biopsies or were too sick to undergo standard biopsies now have a means to be tested.

According to Jackman, another exciting area is the ability to test in the setting of resistance. Patients with EGFR mutations may now have developed resistance in some but not all of their disease. A liquid biopsy can potentially capture things that a needle biopsy might otherwise not.
 


David M. Jackman, MD, medical director of Clinical Pathways, Dana-Farber Cancer Institute, assistant professor of Medicine, Harvard Medical School, discusses the benefits of liquid biopsies for patients with lung cancer.

One of the things that makes liquid biopsies exciting is the ability to test patients whose tumor tissue was inadequate for other testing, Jackman explains. Patients who either had insufficient biopsies or were too sick to undergo standard biopsies now have a means to be tested.

According to Jackman, another exciting area is the ability to test in the setting of resistance. Patients with EGFR mutations may now have developed resistance in some but not all of their disease. A liquid biopsy can potentially capture things that a needle biopsy might otherwise not.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x